RxDoctor Payments Data

Ilene Pardon, MD

Ophthalmology · Ocean, NJNPI 1750452355

Payments from drug & device makers

$1,633in general payments, 2019–2025

Across 91 payments — averaging $17.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$346
  • Sun Pharmaceutical Industries Inc.$200
  • AbbVie$172
  • Tarsus Pharmaceuticals, Inc.$161
  • Bausch & Lomb Americas Inc.$126
  • Oyster Point Pharma, Inc.$120
  • plus $508 from 13 others

What the payments were for

  • Food & beverage$1,633100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,633 in reported general payments places this provider in the 50th percentile of 583 ophthalmology providers in New Jersey.

See all ophthalmology providers in New Jersey

Medicare billing

Part B allowed, 2024
$159,097
Medicare patients
605
Services billed
1,665

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast38$54,353
RestasisCyclosporine39$41,480
Cyclosporine24$16,320
MieboPerfluorohexyloctane/Pf15$10,935
Timolol Maleate73$6,358
Loteprednol Etabonate31$5,883
SimbrinzaBrinzolamide/Brimonidine Tart20$4,728
RocklatanNetarsudil Mesylat/Latanoprost11$4,290
Latanoprost447$4,265
Brimonidine Tartrate15$3,676
Travoprost16$2,541
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol11$1,847
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat74$1,418
Fluorometholone20$1,259
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha58$696

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Xiidra, Miebo$126$65,28853 claims
AbbVieRestasis$172$41,48039 claims
AlconSimbrinza$346$4,72820 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 583 ophthalmology providers in New Jersey.

Other ophthalmology in Ocean

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →